Novartis announced that Scemblix has been granted priority review status by the Food and Drug Administration for treatment of newly diagnosed adult patients with Philadelphia chromosome-positive chronic Myeloid leukemia in chronic phase.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS: